Crisdesalazine Reduces Inflammation in a Mouse Model of Multiple Sclerosis
Author Information
Author(s): Park Su-Min, Oh Yong-Hun, Lim Ga-Hyun, An Ju-Hyun, Lee Jin-Hwan, Gwag Byoung-Joo, Won So-Jung, Seo Kyoung-Won, Youn Hwa-Young
Primary Institution: Seoul National University
Hypothesis
Does crisdesalazine alleviate inflammation and improve symptoms in an experimental autoimmune encephalomyelitis (EAE) mouse model?
Conclusion
Crisdesalazine significantly alleviated clinical symptoms and reduced inflammation and demyelination in the spinal cord of EAE mice.
Supporting Evidence
- Crisdesalazine treatment reduced the severity of clinical symptoms in EAE mice.
- Inflammatory cell infiltration in the spinal cord was significantly decreased with crisdesalazine treatment.
- Demyelination areas in the spinal cord were reduced in the crisdesalazine-treated group.
- Crisdesalazine promoted the transition of macrophages from the M1 to M2 phase.
- Expression of inflammatory cytokines was significantly lower in the treatment group.
Takeaway
Crisdesalazine is a new medicine that helps reduce inflammation and protect nerves in mice with a disease similar to multiple sclerosis.
Methodology
The study used a mouse model of EAE, where mice were treated with crisdesalazine and evaluated for clinical symptoms, inflammatory cell infiltration, and demyelination.
Limitations
The study primarily focused on macrophages and did not explore the effects of crisdesalazine on other immune cells in detail.
Participant Demographics
6-week-old female C57BL/6 mice
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website